Amyl Therapeutics

About

Amyl Therapeutics is a preclinical stage biotechnology company.

Liège,Liege,Belgium
1 - 10
https://www.amyltx.com/

Highlights

Details

Last Funding Type: Series A
Last Funding Money Raised: €8.60M
Industries: Biotechnology,Health Care,Life Science,Medical
Founded date: Nov 1, 2020
Number Of Employee: 1 - 10
Operating Status: Active

Amyl Therapeutics is a preclinical stage biotechnology company. Amyl Therapeutics uses a novel mechanism to bind to the amyloid fold of toxic protein aggregates of various types, including antibody light chain (AL) or transthyretin (TTR) aggregates, which accumulate in peripheral organs to cause systemic amyloidosis diseases, but also amyloid-β (Aβ), Tau, and α-synuclein aggregates, which accumulate in the brain to cause Alzheimer's and Parkinson's diseases.

Funding Rounds

Number of Funding Rounds

Total Funding Amount

2

€18.30M

Amyl Therapeutics has raised a total of €18.30M in funding over 2 rounds. Their latest funding was raised on Jun 3, 2021 from a Series A round.

Announced Date	Round	Money Raised	Number of Investors	Lead Investors	Post Valuation
Jun 3, 2021	Series A	€8.60M	7	Meusinvest (Noshaq)	—	Detail
Jun 3, 2021	Grant	€9.70M	1	Directorate General operational for Economy, Employment and Research	—	Detail

Investors

Number of Lead Investors

Number of Investors

2

8

Amyl Therapeutics is funded by 8 investors. Meusinvest (Noshaq) and Directorate General operational for Economy, Employment and Research are the most recent investors.

Investor Name	Lead Investor	Funding Round
Meusinvest (Noshaq)	Yes	Series A
Directorate General operational for Economy, Employment and Research	Yes	Grant
Ifoghas Investments	—	Series A
6K Venture Capital	—	Series A
Kenneth Buckfire	—	Series A
Merieux Developpement	—	Series A
Sambrinvest	—	Series A
Smedvig	—	Series A